Novel agents for the treatment of pancreatic adenocarcinoma: any light at the end of the tunnel? Highlights from the "2010 ASCO Annual Meeting". Chicago, IL, USA. June 4-8, 2010

Pancreatic cancer is a disease with dismal prognosis and treatment options are limited. Development of novel active compounds is mandatory. A number of pancreatic cancer clinical trials that included a novel agent among their arms were presented at the recent 2010 American Society of Clinical Oncolo...

Ausführliche Beschreibung

Bibliographische Detailangaben

Veröffentlicht in:	Journal of the Pancreas 2010-07, Vol.11 (4), p.324
Hauptverfasser:	Dimou, Anastasios T, Syrigos, Konstantinos N, Saif, Muhammad Wasif
Format:	Artikel
Sprache:	eng
Schlagworte:	Adenocarcinoma - drug therapy Antineoplastic Agents - isolation & purification Antineoplastic Agents - therapeutic use Chicago Congresses as Topic Humans Medical Oncology - methods Medical Oncology - trends Pancreatic Neoplasms - drug therapy Societies, Medical - organization & administration United States
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!